[b]THERAPEUTIC CLASS OVERVIEW: TREATING REFRACTORY HEMATOLOGICAL MALIGNANCIES[/b]


Targeting unmet needs in the treatment of cancer/ hematological malignancies through innovative drug development strategies have witnessed favorable outcomes. Over the past decade, Proteasome inhibitor, Velcade (bortezomib) and the immunomodulatory drugs - Thalomid (thalidomide) and Revlimid (lenalidomide) have become the cornerstone of treatment for patients with Multiple Myeloma (MM) resulting in improved survival. However, eventually all patients relapse and new treatment options for Relapsed/ Refractory Multiple Myeloma (RRMM) are required to further improve survival and quality of life of this group of pts. Two new drugs have successfully fulfilled this need - POMALYST/ IMNOVID (pomalidomide - POM) and Kyprolis (carfilzomib-CFZ) but is there room for more?We expect a similar scenario to unfold in the treatment of Recurrent/ Refractory MDS (RR-MDS, High-Risk MDS), and Relapsed/ Refractory AML (R/R AML). Innovative approach to treating unmet need has been handsomely rewarded in the past through in-licensing or outright acquisition of the mature/nascent product/innovator company at a premium. The report provides an overview of the approved therapies for RRMM, NDMM, AML, MDS, unmet need and limitations of the current SOC for relapsed and refractory pts. The report highlights the competition and commercial opportunity in pursuing these therapy areas - Comprehensive list of the early and late stage drugs in the clinic, their MoA and the companies developing them.


[b]Table of Contents[/b]
Chapters Title Pg No.
1. Executive Summary 33
2. Disease Overview: MDS 34-35
2.1. Unmet Need: MDS
3. Current Standard of Care 35-36
3.1. Supportive Care: Hematopoietic Cytokine
3.2. Low-Intensity Therapy
3.3. High-Intensity Therapy
3.4. Recurrent / Refractory or relapsed MDS
4. Disease Overview: AML 37
5. Current Standard of Care 37-38
5.1. AML pts Younger than 60 years
5.2. AML pts Older than 60 years
6. Unmet Need: AML 38-39
6.1. Relapsed/ refractory AML
7. Late-Stage pipeline Targeting High-Risk or R/R MDS AND R/R AML 39-48
7.1. Estybon
7.2. Vosaroxin
7.3. Quizartinib
7.4. ADI-PEG 20
7.5. BL-8040
8. Late-Stage pipeline Targeting 1st-line Lower Risk MDS 49-51
8.1. Volasertib
8.2. CPX-351
8.3. Sapacitabine
8.4. Oral Rigosrtib
9. Key Milestones of Drugs For RRMDS/RRAML in 2014-15 52
10. Launch Timeline and Commercial Opportunity of Late-Stage Pipeline (RR MDS and RR AML) 53
11. Drivers of M&A/Licensing Deals in MDS/AML 54

[b]To order this report:[/b] http://www.researchonglobalmarkets.com/therapeutic-class-overview-treating-refractory-hematological-malignancies.html

Email: [email protected]
US/CAN: +1 800 986 6819
UK: +44 203 514 2363
India: +91 22 4098 7600
[b]SOURCE:[/b] http://www.researchonglobalmarkets.com
[b]Blog:[/b] www.blog.researchonglobalmarkets.com